menu
    • menu
    [{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Ardelyx","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tenapanor Hydrochloride","moa":"NHE3","graph1":"Nephrology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kyowa Kirin \/ Ardelyx","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Ardelyx"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Reata Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Nephrology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kyowa Kirin \/ Reata Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Reata Pharmaceuticals"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Harvard University","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nephrology","graph2":"Discovery","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Harvard University","highestDevelopmentStatusID":"2","companyTruncated":"Kyowa Kirin \/ Harvard University"}]

    Find Nephrology Clinical Drug Pipeline Developments & Deals by Kyowa Kirin

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kyowa Kirin

                            Japan arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Kyowa Kirin

                            Japan arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bardoxolone Methyl

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Reata Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kyowa Kirin Announces Phase III Study Results of bardoxolone methyl (RTA 402) in Japan and Discontinuation of ...

                            Details : RTA 402 (bardoxolone methyl) is a small-molecule compound licensed from Reata Pharmaceuticals has been designated as a "SAKIGAKE Designation" program for the treatment of diabetic kidney disease, a Phase III clinical study for the indication in Japan.

                            Product Name : RTA 402

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 05, 2023

                            Lead Product(s) : Bardoxolone Methyl

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Reata Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kyowa Kirin

                            Japan arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Kyowa Kirin

                            Japan arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Study Phase : Discovery

                            Sponsor : Harvard University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Harvard University and Kyowa Kirin Enter Strategic Research Alliance

                            Details : The 5-year alliance, established by Harvard’s Office of Technology Development (OTD), aims to fuel scientific collaboration among academic and industry researchers to accelerate discovery and early-stage innovation in translational biomedical science.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 26, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nephrology

                            Highest Development Status : Discovery

                            Sponsor : Harvard University

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kyowa Kirin

                            Japan arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Kyowa Kirin

                            Japan arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tenapanor Hydrochloride

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Ardelyx

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kyowa Kirin Announces a Phase 2 Study Result of tenapanor (KHK7791) for Hemodialysis Patients with Hyperphosph...

                            Details : KHK7791 (Tenapanor) effect of decreasing pill burden of phosphate binders, which is the outcome of a phase 2 study of tenapanor for hemodialysis patients with hyperphosphatemia in Japan, was presented in a poster session virtually at ERA-EDTA 2020 annual...

                            Product Name : Xphozah

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 06, 2020

                            Lead Product(s) : Tenapanor Hydrochloride

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Ardelyx

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth